Company Overview and News
Apple Inc. (AAPL - Free Report) is no doubt a valued customer to have but its recent actions are increasingly speaking otherwise. The recent revelation per a Bloomberg report that Apple will utilize its own chips phasing out Intel’s chips in Mac by 2020 has sent ripples across its supplier base. We believe Apple’s focus on building a closed ecosystem of semiconductor solutions for its own usage will hurt suppliers like Infineon Technologies (IFNNY - Free Report) , Cirrus Logic (CRUS - Free Report) and Qorvo Inc (QRVO - Free Report) .
TOKYO, March 30 (Reuters) - Japanese stocks rose on Friday morning as technology firms such as Tokyo Electron and Advantest jumped in sympathy with a rebound in their U.S. counterparts, which were battered this week on concerns over possible government regulation.
It was an eventful week for Apple (AAPL - Free Report) , a week that included its purchase of a magazine subscription service called Texture, a news leak about its in-house development of MicroLED screens, a report about its sinking brand value, plus some usual ruckus about its business practices, fines and taxes in Europe. Here are some more details-
Apple is designing and producing its own device displays for the first time, using a secret manufacturing facility near its California headquarters to make small numbers of the screens for testing purposes, according to people familiar with the situation.
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
Apple (AAPL - Free Report) is reportedly developing next-generation MicroLED screens for its own use in a secret manufacturing facility near the company’s California headquarters. Per Bloomberg, the company is currently making small number of screens for testing purposes. Apple’s foray into MicroLED display manufacturing has taken the market by surprise. However, we believe that the company has been planning the venture into MicroLED display technology for quite some time.
Apple Inc. AAPL, -0.35% is designing and making its own display screens for the first time at a secret facility near its California headquarters, Bloomberg reported on Monday, citing people familiar with the situation. The company is testing small numbers of the screens as it gears up to invest in the development of next-generation MicroLED screens, Bloomberg reported. MicroLED screens are harder to make than the current OLED screens, as they use different light-emitting compounds and are expected to make devices slimmer, brighter and more power-efficient.
SAN FRANCISCO – Apple Inc. is designing and producing its own device displays for the first time, using a secret manufacturing facility near its California headquarters to make small numbers of the screens for testing purposes, according to people familiar with the situation.
San Francisco: Apple Inc. is designing and producing its own device displays for the first time, using a secret manufacturing facility near its California headquarters to make small numbers of the screens for testing purposes, according to people familiar with the situation.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
There is one way to assure that your supply chain is not impacted by the upcoming trade wars: bring all your manufacturing to the host nation and no longer rely on foreign suppliers.
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
12h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
as of ET